Vanguard Personalized Indexing Management LLC Grows Stock Holdings in Merck & Co., Inc. $MRK

Key Points

• Vanguard Personalized Indexing Management LLC increased its Merck stake by 20.7% in the fourth quarter, adding 66,115 shares and bringing its total holding to 385,886 shares valued at about $40.6 million.
• Several analysts remain constructive on Merck, with recent buy/overweight ratings and an average Wall Street rating of Moderate Buy; the consensus price target is $128.18.
• Merck reported quarterly earnings that beat expectations, and the company also announced a $0.85 quarterly dividend, equal to a $3.40 annualized payout and a 2.9% yield.

Vanguard Personalized Indexing Management LLC boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 20.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 385,886 shares of the company's stock after buying an additional 66,115 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in Merck & Co., Inc. were worth $40,618,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $25,000. IFC & Insurance Marketing Inc. purchased a new position in Merck & Co., Inc. in the 4th quarter valued at approximately $31,000. High Note Wealth LLC increased its stake in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company's stock valued at $31,000 after purchasing an additional 109 shares in the last quarter. Gilpin Wealth Management LLC acquired a new position in Merck & Co., Inc. during the fourth quarter worth $32,000. Finally, Tucker Asset Management LLC acquired a new position in Merck & Co., Inc. during the fourth quarter worth $34,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

MRK has been the topic of several research reports. Barclays assumed coverage on Merck & Co., Inc. in a report on Friday, February 20th. They issued an "overweight" rating and a $140.00 target price on the stock. UBS Group increased their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a research note on Monday, April 13th. Zacks Research raised shares of Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 17th. JPMorgan Chase & Co. lifted their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an "overweight" rating in a research note on Monday, April 6th. Finally, Weiss Ratings downgraded Merck & Co., Inc. from a "hold (c+)" rating to a "hold (c)" rating in a report on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $128.18.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, a poultry biodevice company, which could strengthen Merck’s animal health division and broaden its technology-driven growth opportunities. Merck Animal Health to Acquire TARGAN
• Positive Sentiment: Merck saw unusually heavy call option buying, with traders purchasing 170,441 calls, a sharp jump versus normal volume that often signals bullish expectations from sophisticated investors.
• Positive Sentiment: Wells Fargo reiterated a buy rating on Merck, while another article highlighted that Wall Street’s overall bullish view continues to keep MRK on investors’ radar.
• Neutral Sentiment: Merck has also been featured in broader market commentary and “most searched” lists, suggesting rising attention rather than a new fundamental catalyst.
• Neutral Sentiment: One article noted Merck’s recent trading uptick but said it lagged the broader market, indicating modest price strength rather than a major breakout. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Merck & Co., Inc. Stock Up 0.0%

Shares of NYSE:MRK opened at $119.05 on Monday. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The firm has a market cap of $294.04 billion, a price-to-earnings ratio of 33.54, a PEG ratio of 2.68 and a beta of 0.21. The stock's 50-day moving average price is $116.55 and its two-hundred day moving average price is $113.32. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $125.14.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts' consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company's quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts forecast that Merck & Co., Inc. will post 5.17 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 2.9%. Merck & Co., Inc.'s dividend payout ratio is 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.